Your browser doesn't support javascript.
loading
Cannabinoid Antagonist Drug Discrimination in Nonhuman Primates.
Kangas, Brian D; Zakarian, Ani S; Vemuri, Kiran; Alapafuja, Shakiru O; Jiang, Shan; Nikas, Spyros P; Makriyannis, Alexandros; Bergman, Jack.
  • Kangas BD; Department of Psychiatry, Harvard Medical School, Boston, Massachusetts (B.D.K., J.B.); Behavioral Biology Program, McLean Hospital, Belmont, Massachusetts (B.D.K., A.S.Z., J.B.); and Center for Drug Discovery, Northeastern University, Boston, Massachusetts (K.V., S.O.A., S.J., S.P.N., A.M.) bkangas
  • Zakarian AS; Department of Psychiatry, Harvard Medical School, Boston, Massachusetts (B.D.K., J.B.); Behavioral Biology Program, McLean Hospital, Belmont, Massachusetts (B.D.K., A.S.Z., J.B.); and Center for Drug Discovery, Northeastern University, Boston, Massachusetts (K.V., S.O.A., S.J., S.P.N., A.M.).
  • Vemuri K; Department of Psychiatry, Harvard Medical School, Boston, Massachusetts (B.D.K., J.B.); Behavioral Biology Program, McLean Hospital, Belmont, Massachusetts (B.D.K., A.S.Z., J.B.); and Center for Drug Discovery, Northeastern University, Boston, Massachusetts (K.V., S.O.A., S.J., S.P.N., A.M.).
  • Alapafuja SO; Department of Psychiatry, Harvard Medical School, Boston, Massachusetts (B.D.K., J.B.); Behavioral Biology Program, McLean Hospital, Belmont, Massachusetts (B.D.K., A.S.Z., J.B.); and Center for Drug Discovery, Northeastern University, Boston, Massachusetts (K.V., S.O.A., S.J., S.P.N., A.M.).
  • Jiang S; Department of Psychiatry, Harvard Medical School, Boston, Massachusetts (B.D.K., J.B.); Behavioral Biology Program, McLean Hospital, Belmont, Massachusetts (B.D.K., A.S.Z., J.B.); and Center for Drug Discovery, Northeastern University, Boston, Massachusetts (K.V., S.O.A., S.J., S.P.N., A.M.).
  • Nikas SP; Department of Psychiatry, Harvard Medical School, Boston, Massachusetts (B.D.K., J.B.); Behavioral Biology Program, McLean Hospital, Belmont, Massachusetts (B.D.K., A.S.Z., J.B.); and Center for Drug Discovery, Northeastern University, Boston, Massachusetts (K.V., S.O.A., S.J., S.P.N., A.M.).
  • Makriyannis A; Department of Psychiatry, Harvard Medical School, Boston, Massachusetts (B.D.K., J.B.); Behavioral Biology Program, McLean Hospital, Belmont, Massachusetts (B.D.K., A.S.Z., J.B.); and Center for Drug Discovery, Northeastern University, Boston, Massachusetts (K.V., S.O.A., S.J., S.P.N., A.M.).
  • Bergman J; Department of Psychiatry, Harvard Medical School, Boston, Massachusetts (B.D.K., J.B.); Behavioral Biology Program, McLean Hospital, Belmont, Massachusetts (B.D.K., A.S.Z., J.B.); and Center for Drug Discovery, Northeastern University, Boston, Massachusetts (K.V., S.O.A., S.J., S.P.N., A.M.).
J Pharmacol Exp Ther ; 372(1): 119-127, 2020 01.
Article en En | MEDLINE | ID: mdl-31641018

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Síndrome de Abstinencia a Sustancias / Discriminación en Psicología / Modelos Animales de Enfermedad / Antagonistas de Receptores de Cannabinoides Tipo de estudio: Prognostic_studies Límite: Animals Idioma: En Año: 2020 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Síndrome de Abstinencia a Sustancias / Discriminación en Psicología / Modelos Animales de Enfermedad / Antagonistas de Receptores de Cannabinoides Tipo de estudio: Prognostic_studies Límite: Animals Idioma: En Año: 2020 Tipo del documento: Article